Monthly reductions in seizure frequency of 90.9% among participants treated for ≥48 months in the OLE, with 38% achieving ≥1 year of seizure freedomNew X-TOLE OLE data analysis supports the ability to ...
Xenon Pharmaceuticals (XENE) announced new data highlighting its commitment in epilepsy, including interim 48-month data from its ongoing X-TOLE ...
A team of researchers has announced their observation and measurement of the decay of Xenon-124, the rarest ever recorded. It ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback